Results 131 to 140 of about 1,336,020 (297)

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

PROMETHEUS Payment: What's the Score? [PDF]

, 2009
Explains the scorecard used in "Provider payment Reform for Outcomes, Margins, Evidence, Transparency, Hassle-reduction, Excellence, Understandability, and Sustainability" (PROMETHEUS) to determine provider payments based on evidence-informed case ...
Alice G. Gosfield, Francois de Brantes
core  

Ethnic minority patients’ experiences of filling in translated patient-reported outcome measures

Journal of Public Health Research
Background: Problems assessing migrant patients’ pain may cause inadequate treatment. Standardised patient-reported outcome measures (PROMs) are used as basis for tailoring treatment plans. This study investigates patients’ experiences of filling in PROMs translated into their home language.
Lise-Merete Alpers, Ingrid Hanssen
openaire   +3 more sources

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Risk Factors for Hospital Malpractice Exposure: Implications for Managers and Insurers [PDF]

, 1991
The possibility of identifying certain variables that might serve as predictors of above- or below-average medical malpractice claims experience was explored.
Katz, Patricia P., Luft, Harold S., Pinney, Douglas G.   +2 more
core   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

How patient-reported outcomes and experience measures (PROMs and PREMs) are implemented in healthcare professional and patient organizations? An environmental scan

Journal of Patient-Reported Outcomes
Background Patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) are becoming essential parts of a learning health system, and using these measures is a promising approach for value-based healthcare. However, evidence
Véronique Lowry, Vanessa Tremblay-Vaillancourt, Priscilla Beaupré, Marie-Dominique Poirier, Marie-Ève Perron, Jessica Bernier, Anaëlle Morin, Caroline Cormier, Jeannie Haggerty, Sara Ahmed, Magaly Brodeur, Geneviève David, Sylvie Lambert, Maude Laberge, Diana Zidarov, Regina Visca, Thomas G. Poder, Hervé Tchala Vignon Zomahoun, Maxime Sasseville, Marie-Eve Poitras   +19 more
doaj   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Using patient-generated health data more efficient and effectively to facilitate the implementation of value-based healthcare in the EU – Innovation report

Computational and Structural Biotechnology Journal
Healthcare services and products are rapidly changing due to the development of new technologies, offering relevant solutions to improve patient outcomes.
Frans Folkvord, Jim Ingebretsen Carlson, Manuel Ottaviano, Diego Carvajal, Liss Hernandez Gonzalez, Rens van de Schoot, Eva Turk, Jordi Piera-Jiménez, Caridad Pontes, Marina Ramiro-Pareta, Gerard Carot-Sans, Eva Podovšovnik, Vesna Levašič, Kathrin Scheckenbach, Martin Wagenmann, Aron Szpisjak, Bogi Eliasen, Joe-Max Wakim, Martin Ernst, Yvonne Prinzellner, Nadine Bol, Linwei He, Emiel Krahmer, Clàudia Navarro, Laia Juan, Davide Guerri, Laura Pinna, Carmela Genovese, Luciano Benetti, Chiara Macagnano, Franco Chiarugi, Johannes Peeters, Ludovico Pedullà, Giampaolo Brichetto, Paola Zaratin, Seldag Gunes Peschke, Lutz Peschke, Giuseppe Fico   +37 more
doaj   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source